Skip to main content
Egyptian Journal of Medical Human Genetics
Download PDF

Prognostic significance of miR 499 expression and Helicobacter pylori infection in malignant lesions of gallbladder cancer: a clinicopathological study

Egyptian Journal of Medical Human Genetics volume 25, Article number: 96 (2024) Cite this article

Abstract

Background

Gallbladder cancer (GBC) is an infrequent type of malignant neoplasm worldwide. There are a number of risk factors that increase a person's likelihood of developing GBC. Gallbladder inflammatory (GID) diseases including cholelithiasis increase the risk of GBC, and this is further complicated by the fact that Helicobacter pylori (H. pylori) infection is extremely common in gastrointestinal tract in India. Since both miR 499 and H. pylori infection are found to be linked with tumor progression and metastasis, therefore there is a possibility that H. pylori might be involved in inflammation via dysregulation of miR 499. The study was designed to investigate the association of miR 499 expressions with H. pylori infection and their correlation with clinicopathological parameters of GBC.

Material and methods

The hundred three tissue samples used in this study are categorized into GID (n = 55) and GBC (n = 48). The expression of miR-499 was examined by using the Livak method for relative gene expression analysis. The presence/absence of H. pylori infection was examined by RT-PCR (Liferiver Helicobacter pylori RT-PCR Kit).

Results

Helicobacter pylori infection and GBC/GID cases were not significantly correlated. Decreased expression of miR 499 was observed in GBC (1.6 fold) as compared to GID patients (P < 0.0001). Low miR 499 expression was found to significantly correlate with tumor differentiation (P = 0.017), advanced staging (P = 0.004) and liver metastasis (P = 0.036). Multivariate regression analysis showed significant association of overall survival with low miR 499 expressions.

Conclusion

miR 499 may be considered as a useful prognostic biomarker in GBC progression.

Highlights

  • H. pylori infection is not significantly associated with gallbladder cancer.

  • miR -499 expression is significantly correlated with tumor differentiation, advanced staging and liver metastasis.

  • Positive significant association is observed between miR 499 and overall patient survival.

Introduction

Gallbladder cancer (GBC) is relatively rare, ranked 24th among the most common highly aggressive type of malignant neoplasm of gastrointestinal tract cancer (Globocan) [1]. It has been reported that the incidence of GBC is almost 4–6 times greater in North Indian population than South India. (Delhi: 4.1/100,000 men, 9.5/100,000 women and Bengaluru 1.4/100,000 men, 1.7/100,000 women) [2]. Most of the GBC cases are diagnosed at the advanced stages due to the lack of clinical appearance, which are nonspecific. The majority of cases are found co-incidentally at the time of histopathological examination of cholecystectomy [3]. GBC is reported with high rate of recurrence and metastasis due to poor response to chemotherapy and radiotherapy. There are a number of risk factors responsible for the development of GBC. Cholecystitis is also often diagnosed in younger age group persons. Cholelithiasis (gall stones) has also been implicated in the development of GBC [4]. Gallstones appear to be more common in ethnic groups with higher rates of GBC, where they appear to be more likely to be present and increase the risk of GBC by more than threefold. [5]. This is made even more difficult by the fact that Helicobacter pylori (H. pylori) infection in the gastrointestinal tract is extremely widespread in India and is recognized as a certain cause of cancer by the International Agency for Research on Cancer. [6]. It is now recognized as the main and specific infectious cause of stomach cancer in the world. It has been also reported that H. pylori is associated with pathogenesis of human cholelithiasis and cholecystitis and closely correlates with gastrointestinal cancers [7]. H. pylori infections have also been seen in gallbladder, which results in chronic persistent inflammation. Furthermore, research performed emphasized that gallbladder metaplasia, adenomatous hyperplasia and dysplasia changes were more frequent in patients with positive H. pylori infection [8].

H. pylori infection has been reported to be correlated with dysregulation of some small non-coding miRNAs [9]. The six biological capabilities acquired during tumorigenesis viz tumor proliferation, differentiation, evasion of apoptosis, defective cell cycle, an induction of metastasis and angiogenesis, have been described as hallmarks for human cancer [10]. The role of miRs in various cancer types, including breast, squamous cell carcinoma of the head and neck, and bladder cancer, has been the subject of recent studies, but very few have focused on GBC [11,12,13,14,15].

miR 499 has been found to play role in modulation of expression of genes related to cancer resulting in tumorigenesis and resistance to chemotherapy, thus contributes to poor prognosis [16]. Few studies have specifically highlighted the role of miR 499 expression role in various cancers. [17, 18].

MiRs are involved in regulating the pro-inflammatory immune response induced during H. pylori infection. Cancer is caused by the accumulation of mutations, epigenetic modifications, and defective cellular function that may result from the long-term interaction of bacterial and inflammatory mediators with dysregulated miRNA expression. [19]. Since both miR 499 and H. pylori infection, have been found to be involved in tumor progression and metastasis, there is a possibility that H. pylori might be involved in inflammation via dysregulation of miR 499. Thus the present study provides a hypothetical association of miR 499 expressions to H. pylori infection and their correlation with clinicopathological parameters of GBC.

Materials and methods

Patients

The present study is a prospective study, including 103 subjects of gallbladder disease. All the recruited patients were grouped into GBC (n = 48); and GID (n = 55). The tissue samples were collected from August 2014 to September 2018. The formula n = Z2pq/L2 was used to determine the sample size, where (p = 57.83%, q = 100-p, Type I error α = 5%, Allowance error L = 1/4th of p, Power of study = 75%, Data loss = 10%) The final sample size is 48 for each group [20].

The tissue samples of both GBC and GID subjects were collected in two different containers. One portion of the tissue sample was collected in container containing formalin (10%) which was embedded in paraffin to prepare paraffin embedded blocks for histopathological examination. All histopathologically confirmed cases (GBC; n = 48 and GID; n = 55) were included in the study. The American Joint Committee on Cancer (AJCC) Tumor node metastasis (TNM) staging 7th edition recommended guidelines was used for pathological staging of cases [21]. The other part of the tissue was collected in a container containing RNA later (Sigma–Aldrich, USA), stored at—80 °C for RNA isolation to study miR 499 expressions as well as DNA isolation H. Pylori detection.

Inclusion criteria

All patients who underwent biopsy of metastatic lesion or radial surgery of primary GBC and GID though laparoscopic or open cholecystectomy were included in the study.

Exclusion criteria

Patients diagnosed with any other types of cancer or who underwent chemotherapy or radiotherapy or were operated earlier and those with any immunodeficiency disorder were excluded from the study.

Methods

H. pylori detection

Helicobacter pylori real-time PCR kit (Liferiver Helicobacter pylori Real-Time PCR Kit, China) was used for DNA isolation as per the protocol provided by the manufacturer. The quality of the DNA was checked by agarose gel electrophoresis using a gel-doc system (UVP, DIGI DOC–IT System, USA). Nanodrop 2000 Spectrophotometer from Thermo Fisher, USA, was used to measure the concentration and purity of the obtained DNA. Quantitative real-time PCR was performed using (Applied Biosystems, StepOnePlus RT-PCR, version 2.3, Canada) to detect the H. pylori DNA in tissue samples of both GBC and GID. A 40 µl reaction mixture was prepared (36 µl master mix, 4 µl extracted DNA). The RT step was performed at 37 °C for 2 min(one cycle), followed by 2 min at 94 °C. The PCR step comprised 40 cycles of denaturation each for 15 s at 93 °C and annealing/extension for 1 min at 60 °C. Each run included negative and positive controls from the real-time kit to ensure that the sample processing, amplification, and detection steps were carried out correctly.

miR extraction and RT-PCR assay

The GBC/GID tissue samples stored in RNA later were used for the isolation of total ribonucleic acid (RNA) by using the mirVANA ™ miRNA isolation Kit, USA. The isolated RNA was quantified using nanodrop spectrophotometer (Thermo 2000C model, Thermo Fisher, USA) and the quality of RNA was checked by measuring A260/A280. The integrity of isolated RNA was also checked by agarose gel electrophoresis using 1.0% agarose gel stained with 0.5 μg/ml EtBr using gel doc (UVP, DIGI DOC –IT System, USA). The extracted total RNA was kept at − 20 °C. cDNA synthesis of miR 499 and RNU6B (internal reference gene) was synthesized from 2 µg of total RNA by using TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, (USA) and TaqMan Universal PCR Master Mix, No AmpErase (Uracil-N glycoslyase). Individual RT-PCR assay were run in 20 μL reaction volume in a RT-PCR machine (Applied Biosystems StepOnePlus™ system version 2.3, Canada) to detect miR 499 expressions in tissue. Each sample was examined in triplicate. The thermal cycling conditions consisted of optional AmpErase UNG activity and enzyme activation hold at (50 °C for 2 min, 95 °C for 10 min), respectively. Additionally, 40 PCR cycles of denaturation at were performed at 95 °C for 15 s followed by annealing and extension step at 60 °C for 60 s. The cycle threshold (Ct) value was recorded for both miR 499 and RNU6B, and the relative quantification of target miRNA expression was expressed as (2−ΔΔCt), where ΔCt = Ct miR 499-Ct RNU6B (Livak method for relative gene expression analysis) [22]. The correlation was observed between Ct values of target miR with reference to RNU6B. The Livak method is used for relative quantification of miR 499 expression analysis.

Statistical analysis

Software used for the statistical analysis was SPSS (version 20; IBM, Chicago, IL, USA) Student t-test was carried out to compare the expression level of miR 499 between GBC and GID. Chi-square or Fisher exact test was performed for association between miR 499 and H. pylori infection with cliniopathological parameters.

The survival analysis was done by Kaplan–Meier analysis and Cox’s multivariate regression using log-rank test, along with hazard ratio (HR) and corresponding 95% confidence interval (CI).

Results

Primary results

Age and sex distribution and their clinical condition

The present study was carried out with an aim to correlate H. pylori infection, miR 499 expression with clinicopathological parameters in GBC (n = 48) and GID (n = 55) patients. All the 55 patients of GID had a mean age 49.25 ± 1.59; range (20–65), percentage of females was 65.4% (36/55) and presence of gallstone was found in 69% (38/55). Forty eight patients of GBC had a mean age 51.10 ± 1.41; range (28–70), percentage of females was 68.7% (33/48) and presence of gallstones was found in 62.5% (30/48). Menstrual history with postmenopausal status was found in 63.6% (21/33) and pre-menopause status was found in 36.3% (12/33) females with GBC. Well-differentiated adenocarcinoma was observed in 39.5% (19/48), moderately and poorly differentiated carcinoma in 60.4% (29/48). GBC patients in stage I–II were 41.6% (20/48) and 58.3% (28/48) were in with stage III-IV. Liver metastasis was found in 22.9% (11/48) (Table 1).

Table 1 General characteristics of the study subjects
Full size table

Secondary results

Association between downregulation of miR 499 and H. pylori positivity in GBC

Out of 103 gallbladder tissue samples, H. pylori infection was found positive in 25% (12/48) GBC, and in 23.6% (13/55) GID patients. There was no significant association was observed between H. pylori infection and GBC/GID cases. Decreased expression of miR 499 was observed in GBC (1.6 fold) as compared to GID patients (P < 0.0001). In relation with H. pylori infection, there was no significant difference in miR 499 expression between H. pylori present and H. pylori absent samples (P = 0.6455). The present data show no association between miR 499 and H. pylori infection in GBC. However, miR 499 expression levels were found to be statistically significant with GBC when compared with GID cases (Fig. 1a, b).

Fig. 1
figure 1

(A) miR 499 has significantly lower expression level in GBC than GID cases (P < 0.0001). (B) No significant difference was observed between miR 499 expression and H. pylori positive/H. pylori negative GBC cases. (C) Statistically significant correlation was observed between miR 499 expression levels in different clinical parameters. (a) Tumor differentiation (P = 0.0171; well vs poor/moderate). (b) Tumor stage (P = 0.0004; Stage I–II vs. III–IV). (c) Liver metastasis (P = 0.036; Negative vs. Positive)

Full size image

Association of miR 499 expression and H. pylori infection with clinicopathological parameters

All the clinical data including tumor size, differentiation, staging, lymphatic invasion and liver metastasis were obtained from patients’ information sheet containing clinical records available in the department. No significant association was found between H. pylori infection and clinicopathological parameters in GBC patients.

All 48 (GBC patients) were divided into two groups using the median expression level of miR-499 (0.193) as a cutoff point. GBC patients who expressed values below the median expression level were placed in the low expression group (mean miR 499 expression value: 0.092; n = 24), and patients whose expression levels were higher than the cutoff value were placed in the high expression group (mean miR 499 expression value: 0.486; n = 24). Significant correlation was found between low expression of miR 499 with tumor differentiation (P = 0.017), advanced staging (P = 0.0004) and liver metastasis (P = 0.036) (Fig. 1c), whereas no significant correlation of miR 499 was observed with gallstones, tumor size, lymphatic invasion, tobacco pan masala chewers, age and sex (Table 2).

Table 2 Correlation of miR 499 and H. pylori infection with various cliniopathological parameters for gallbladder cancer patients
Full size table

miR 499 downregulation is associated with poor prognosis of GBC patients

Patients of GBC were followed up to 36 months through phone calls and routine hospital visit. Kaplan Meier method and log-rank test were used to found the correlation between the median overall survivals of GBC patients with low miR 499 expression and those with high miR 499 expressions. Positive significant correlation was observed between miR 499 expressions and overall survival. Poor survival rates were observed in patients with low miR 499 expression than patients with high miR 499 expressions: P < 0.0001, HR 0.2486, 95% CI 0.1223–0.5056; 10 months (low miR 499) versus 24 months (high miR 499). However no significant correlation was found between H. pylori infection and overall survival status: P = 0.431, HR 0.743, 95% CI 0.3553–1.556 (Fig. 2).

Fig. 2
figure 2

Kaplan–Meier Curves for overall survival of GBC patients. (A) No significant difference was observed between overall survival and H. pylori positive/H. pylori negative GBC cases. (P = 0.4314). (B) The overall survival of patients with low miR-499 expression level was significantly poorer than those with high miR-499 expression in relation to relative quantification (P < 0.0001)

Full size image

Clinicopathological parameters related to three years overall survivals of patients were examined by using univariate and multivariate analyses. Univariate analysis showed significant correlation between overall survival and tumor size, tumor differentiation, staging, lymphatic invasion, liver metastasis and low miR 499 expressions which were predictors of poor survival. Multivariate regression analysis showed significant association of overall survival with low miR 499 expressions and was found to be an independent risk factor for poor prognosis of GBC (Table 3).

Table 3 Univariate and multivariate analysis of clinicopathological parameters of overall survival in GBC patients
Full size table

Discussion

In the current study, miR 499 expressions were analyzed in GBC and GID. Due to inflammatory role of miR 499 in cancer, it was hypothesized that miR 499 expressions might be influenced by the H. pylori infection and it may play vital role in GBC progression. miR 499 was found to be downregulted in GBC patients (1.6 fold) versus GID patients, whereas no significant correlation was found between H. pylori infection and miR 499 expression.

miR 499 plays a vital role in etiology of cancer by targeting the regulation of Forkhead box protein O4, Programmed cell death protein, and sex determining region Y-box 6 gene expression [23]. Additionally, different types of miRs have also been shown to affect the progression of GBC [24, 25]. Particularly, miRNA-499 was found to act as a biological indicator for the prognosis of hepatocellular carcinoma. Previous research revealed that histone deacetylases (HDAC1-3) stimulated the proliferation of HCC cells by downregulating miR-499, indicating that miR-499 may function as a tumor suppressor [26]. However, the precise molecular pathways by which miR-499 regulates the development of GBC remain unclear.

miR 499 and H. pylori infection are thought to important because they mediate the inflammatory process. Long-term infection of H. pylori leads to inflammation and inflammation in combination with oncogenic activation, promotes tumorigenesis [27]. It has been reported that miR-146a negatively regulates H. Pylori—triggered interleukin (IL)-8 and plays a vital role in a negative feedback loop to modulate inflammation [28].

Very few studies have been done in relation to miR 499 expression in GBC cancers. Moreover, studies are available in other cancers, reported that miR 499 promote metastasis by targeting gene FOXO4 in colon cancer [18]. Another study on non-small cell lung cancer patients has reported that miR 499 functions as tumor suppressor in vitro and in vivo by targeting VAV3 [29]. Another study by Li et al. [30] has reported that miR 499 rs376444 polymorphism has been significantly associated with lung cancer. According to the Zhang et al., miR 499 rs3746444 polymorphism has been linked to a high risk of oral cancer [31]. MiR 499 polymorphism has been found to be correlated with increased risk of hepatocellular carcinoma [32]. Additionally, miR 499 in other cancers has been found to be significantly correlated with clinicopathological parameters. Li et al. have revealed a significant correlation between serum miR 499 expressions and advanced stage and poor prognosis in lung cancer [33]. miR 499 has been found to be associated with stage I-IIIA in lung cancer [17].

In the present study, miR 499 expression levels was determined in GBC and GID tissues using RT-PCR. A statistically significant correlation was found between low miR 499 expression levels and tumor differentiation, staging and liver metastasis, while no significant correlation was found between miR 499 and variables such as gender, age, tumor size and lymphatic invasion. Furthermore, no significant correlation was observed between H. pylori infection and clinicopathological manifestations. A similar study has reported with high expression of miR 146a in primary gastric cancer with no clear link to H. pylori infection [28]. Similar to our previous study, no significant association was observed between GBC and demographical parameters (gallstone presence, Smoking, Tobacco chewing, and pain in abdomen) [34].

Kaplan–Meier analysis on patients overall survival revealed its association with reduced miR 499 expression level when compared with high miR 499 levels in GBC patients. MiR 499 was observed as an independent predictor of prognosis in GBC patients by a multivariable Cox propositional hazards model. However, no significant correlation was found between overall survival and H. pylori infection in GBC. Similar results have been reported for association between low miR 499 expression levels and overall survival in non-small cell lung patients [29]. According to the available literature related to GBC and miR 499, this is the first study, reporting a negative significant correlation between miR 499expression in GBC progression which is independent of H. pylori infection.

Conclusion

The outcome of the present study showed statistically significant correlation between low expression of miR 499 and tumor differentiation, higher stage and was found to be associated with GBC progression. Thus miR 499 may be considered as a useful prognostic biomarker in GBC progression. Further studies are required with a larger sample size with other miRNAs to validate the results with more specificity. This would lead to development of a novel prognostic and therapeutic biomarker for GBC.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

GBC:

Gallbladder cancer

GID:

Gallbladder inflammatory disease

H. Pylori :

Helicobacter pylori

miR:

Micro RNA

GIT:

Gastrointestinal tract

AJCC:

American Joint Committee on Cancer

TNM:

Tumor node metastasis

PCR:

Polymerase chain reaction

DNA:

Deoxyribonucleic acid

RNA:

Ribonucleic acid

UNG:

Uracil-N glycoslyase

CT:

Cycle threshold

HR:

Hazard ratio

CI:

Confidence interval

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71:209–249

    Article  PubMed  Google Scholar 

  2. Indian Council of Medical Research. National Centre for Disease Informatics & Research, National Cancer Registry Programme, Report of National cancer registry Program 2020. Comparison of cancer incidence and patterns of all population based cancer registries. Accessed on 20 Dec 20 2020

  3. Misra K, Patel S, Patel K, Ladwa M, Mehta R (2023) Incidental gallbladder carcinoma in routine cholecystectomy specimens at tertiary care hospital. Asian J Med Sci 14(10):246–250

    Article  Google Scholar 

  4. Halaseh SA, Halaseh S, Shakman R (2022) A Review of the etiology and epidemiology of gallbladder cancer: what you need to know. Cureus 14(8):e2826

    Google Scholar 

  5. Shaffer EA (2009) Gallbladder cancer: the basics. Gastroenterol Hepatol 4(4):737–741

    Google Scholar 

  6. Lim K, Lee A, Jiang X, Teng T, Shelat V (2023) The link between Helicobacter pylori infection and gallbladder and biliary tract diseases: a review. Ann Hepatobiliary Pancreat Surg 27(3):241–250

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wang L, Chen J, Jiang W, Cen L, Pan J, Yu C et al (2021) The relationship between helicobacter pylori infection of the gallbladder and chronic cholecystitis and cholelithiasis: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2:1–11

    CAS  Google Scholar 

  8. Di Z, Guan W-B, Wang J-D, Zhang Y, Gong W et al (2013) A comparative study of clinicopathological features between chronic cholecystitispatients with and without Helicobacter pylori infection in gallbladder mucosa. PlosOne 8(7):e70265

    Article  Google Scholar 

  9. Adami B, Tabatabaeian H, Ghaedi K et al (2019) MiR-146a is deregulated in gastric cancer. J Cancer Res Ther 15:108–114

    Article  PubMed  CAS  Google Scholar 

  10. Hanahan D (2022) Hallmarks of cancer: new directions. Cancer Discov 12:31–46

    Article  PubMed  CAS  Google Scholar 

  11. Fard G, Sasi AK, Abak A, Shoorei H, Khoshkar A, Taheri M (2021) Contribution of miRNAs in the pathogenesis of breast cancer. Front Oncol 11:768949

    Article  Google Scholar 

  12. Vahabi M, Blandino G, Agostino SD (2021) MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies. Transl Cancer Res 10:3090–3110

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Das S, Hayden J, Sullivan T, Rieger-Christ K (2023) The roles of miRNAs in predicting bladder cancer recurrence and resistance to treatment. Int J Mol Sci 24:964

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Chandra V, Kim J, Mittal B, Rai R (2016) MicroRNA aberrations: an emerging field for gallbladder cancer management. World J Gastroenterol 22(5):1787–1799

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Fatima N, Srivastava AN, Nigam J, Raza ST, Rizvi S, Siddiqui Z (2019) Low expression of MicroRNA335–5p is associated with malignant behavior of gallbladder cancer: a clinicopathological study. Asian Pac J Cancer Prev 20(6):1895–1900

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Qiu F, Yang L, Ling X, Yang R, Yang X, Zang L et al (2015) Sequence variation in mature microRNA-499 confers unfavorable prognosis of lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 21(7):1602–1613

    Article  PubMed  CAS  Google Scholar 

  17. Ma YS, Shi BW, Lu HM, Xie PF, Xin R, Wu ZJ et al (2021) MicroRNA-499 serves as a sensitizer for lung cancer cells to radiotherapy by inhibition of CK2α-mediated phosphorylation of p65. Mol Ther Oncolyt 21:171–182

    Article  Google Scholar 

  18. Wang J, Li J, Chen L, Fan Z, Cheng J (2020) MicroRNA-499 suppresses the growth of hepatocellular carcinoma by downregulating astrocyte elevated gene-1. Technol Cancer Res Treat 19:1533033820920253

    PubMed  PubMed Central  CAS  Google Scholar 

  19. Polakovicova I, Jerez S, Wichmann A, Sandoval-Bórquez A, Carrasco-Véliz N (2018) Role of microRNAs and exosomes in helicobacter pylori and epstein-barr virus associated gastric cancers. Front Microbiol. https://doi.org/10.3389/fmicb.2018.00636

    Article  PubMed  PubMed Central  Google Scholar 

  20. Peng HH, Zhang YD, Gong LS, Lui WD, Zang Y (2013) Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma. Onco Targets Ther 11:1625–1630

    Google Scholar 

  21. Edges SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474

    Article  Google Scholar 

  22. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25(4):402–408

    Article  PubMed  CAS  Google Scholar 

  23. Li X, Wang L, Jia Z, Cui Q, Zhang C, Wang W et al (2013) MiR 499 regulates cell proliferation and apoptosis during late-stage cardiac differentiation via Sox6 and cyclin D1. PLoS ONE 8(9):e74504

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Ueta E, Tsutsumi K, Kato H, Matsushita H, Shiraha H, Fujii M et al (2021) Extracellular vesicle-shuttled miRNAs as a diagnostic and prognostic biomarker and their potential roles in gallbladder cancer patients. Sci Rep 11:12298

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Xue XY, Liu YX, Wang C, Gu XJ, Xue ZQ, Zang XL et al (2020) Identification of exosomal miRNAs as diagnostic biomarkers for cholangiocarcinoma and gallbladder carcinoma. Signal Transduct Target Ther 5:77

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Buurman R, Gurlevik E, Schaffer V et al (2012) Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143(3):811–820

    Article  PubMed  CAS  Google Scholar 

  27. Díaz P, Valderrama MP, Bravo J, Quest AF (2018) Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol 9:5

    Article  PubMed  PubMed Central  Google Scholar 

  28. Săsăran MO, Meliț LE, Dobru ED (2021) MicroRNA modulation of host immune response and inflammation triggered by Helicobacter pylori. Int J Mol Sci 22(3):1406

    Article  PubMed  PubMed Central  Google Scholar 

  29. Li M, Zhang S, Wu N, Wu L, Wang C, Lin Y et al (2016) Overexpression of miR 499 inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3. Sci Rep 14(6):23100

    Article  Google Scholar 

  30. Li D, Zhu G, Di H, Li H, Lui X, Zhao M et al (2016) Associations between genetic variants located in mature microRNAs and risk of lung cancer. Oncotarget 7(27):41715–41724

    Article  PubMed  PubMed Central  Google Scholar 

  31. Zhang E, Xu Z, Duan W, Huang S, Lu L (2017) Association between polymorphisms in premiRNA genes and risk of oral squamous cell cancer in a Chinese population. PLoS ONE 12(6):e0176044

    Article  PubMed  PubMed Central  Google Scholar 

  32. Qiu D, Han F, Zhuang H (2018) MiR 499 rs3746444 polymorphism and hepatocellular carcinoma risk: a Meta analysis. J Can Res Ther 14:S490–S493

    Article  CAS  Google Scholar 

  33. Li M, Zhang Q, Wu L, Jia C, Shi F, Li S et al (2014) Serum miR 499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer. Oncol Rep 31:1961–1967

    Article  PubMed  CAS  Google Scholar 

  34. Fatima N, Srivastava AN, Nigam J, Tandon N, Ahmad R, Kumar V (2019) Clinicopathological correlation of cancer stem cell markers Oct-4 and CD133 expression as prognostic factor in malignant lesions of gallbladder: an immunohistochemical study. Indian J Pathol Microbiol 62(3):384–390

Download references

Acknowledgements

We would like to acknowledge the entire research team of Era’s Lucknow Medical College for their support and contributions in this study

Funding

For this study, no fund or other research grant support was received.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Era’s Lucknow Medical College and Hospital, Lucknow, India

    Naseem Fatima & Syed Tasleem Raza

  2. Department of Metabolic Research, Era’s Lucknow Medical College and Hospital, Lucknow, India

    Zainab Siddiqui

  3. Department of Biotechnology, Era’s Lucknow Medical College and Hospital, Lucknow, India

    Saliha Rizvi & Ale Eba

  4. Department of Surgical Oncology, King George’s Medical University, Lucknow, 226003, India

    Mohit Singh & Vijay Kumar

Authors
  1. Naseem Fatima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Syed Tasleem Raza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohit Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saliha Rizvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zainab Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ale Eba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vijay Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NF helped in methodology, data curation, formal analysis, interpretation and writing of the manuscript. STR done supervision and revision of the draft. MS performed clinical data collection, interpretation. SR helped in manuscript preparation. ZS performed statistical analysis and interpretation of data. AE helped in methodology, writing and editing of the manuscript. VK provided the necessary study material and helped in reviewing, supervision and revision of the draft.

Corresponding author

Correspondence to Vijay Kumar.

Ethics declarations

Ethics approval and consent to participate

According to the Helsinki declaration, the study was approved by the institutional ethics committee (ELMC/R_Cell/EC/2014, August 11, 2014). All the patients who were enrolled have given their written informed consent in both English and Hindi languages.

Consent for publication

Written informed consent for publication was obtained from all the patients who were enrolled.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fatima, N., Raza, S.T., Singh, M. et al. Prognostic significance of miR 499 expression and Helicobacter pylori infection in malignant lesions of gallbladder cancer: a clinicopathological study. Egypt J Med Hum Genet 25, 96 (2024). https://doi.org/10.1186/s43042-024-00569-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43042-024-00569-4

Keywords